Advances in CNS drug development

Advances in CNS drug development

The global prevalence of diseases affecting the central nervous system (CNS) demands the development of efficacious therapies for these unmet needs. However, drug development for CNS diseases is complicated by a limited ability to measure whether a drug candidate is accessing and affecting the human brain, particularly in early-stage human trials. Research by Dr Eugenii (Ilan) Rabiner and his colleagues: Dr […]

Read More…